Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 07, 2013 16:10 ET | Source: Novavax, Inc.

Novavax Reports Third-Quarter 2013 Financial Results

ROCKVILLE, Md., Nov. 7, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant...
October 30, 2013 16:58 ET | Source: Novavax, Inc.

Novavax to Report Third Quarter 2013 Financial Results on November 7, 2013

ROCKVILLE, Md., Oct. 30, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that it will host a conference call and live webcast to report its third quarter 2013 financial results on...
October 07, 2013 16:35 ET | Source: Novavax, Inc.

Novavax Initiates Dose-Confirmatory Phase 2 Clinical Trial of its RSV Vaccine Candidate

ROCKVILLE, Md., Oct. 7, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that enrollment has begun in a Phase 2 dose-confirmatory clinical trial of its respiratory syncytial virus...
September 27, 2013 11:29 ET | Source: Novavax, Inc.

Novavax Completes $100 Million Public Offering of Common Stock

ROCKVILLE, Md., Sept. 27, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced the closing of its previously announced underwritten public offering of 31,846,950 shares of its common...
September 24, 2013 08:02 ET | Source: Novavax, Inc.

Novavax Prices Public Offering of Common Stock

ROCKVILLE, Md., Sept. 24, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that it has priced an underwritten public offering of 27,693,000 shares of common stock at a price of...
September 24, 2013 08:00 ET | Source: Novavax, Inc.

Novavax to Initiate Seasonal and Pandemic Influenza Trials in Collaboration With BARDA

Quadrivalent Seasonal Influenza Clinical Trial to start in 1Q2014 Pandemic Influenza Clinical Trial to start in the U.S. in 1H2014 Proprietary Adjuvant Matrix-M to be used in the Pandemic...
September 17, 2013 18:25 ET | Source: Novavax, Inc.

Novavax to Host an Analyst and Investor Update Call With Webcast

ROCKVILLE, Md., Sept. 17, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company creating novel recombinant nanoparticle vaccines and vaccine adjuvants, today...
September 13, 2013 09:03 ET | Source: Novavax, Inc.

Novavax Highlights Positive Results From Partner's Clinical Trial of Vaccine Using Matrix-M(TM)

Genocea Biosciences' Herpes Simplex Therapeutic Vaccine uses Matrix-M adjuvant Phase 1/2A U.S.-based clinical trial enrolled 143 volunteers with moderate-to-severe HSV-2 Two highest dose...
September 11, 2013 08:30 ET | Source: Novavax, Inc.

ICAAC Presentations Highlight Potential Protective Effects of Novavax' RSV Vaccine Candidate

ROCKVILLE, Md., Sept. 11, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage biopharmaceutical company creating novel recombinant nanoparticle vaccines and vaccine adjuvants, today...
September 05, 2013 08:30 ET | Source: Novavax, Inc.

Novavax to Present at the 2013 Stifel Nicolaus Healthcare Conference

ROCKVILLE, Md., Sept. 5, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Stanley C. Erck, President and Chief Executive Officer, will...